8 completed, 2 active not recruiting, 1 not yet recruiting, 1 terminated. 9 Phase 2, 5 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 6, Active not recruiting 1, Not yet recruiting 1, Terminated 1 |
| Phase 1 | 5 | Completed 4, Terminated 1 |
| Phase 3 | 2 | Active not recruiting 1, Completed 1 |
Follow tisotumab vedotin: new trials by email Literature Review of tisotumab vedotin trials Research Report on tisotumab vedotin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tisotumab Vedotin in Squamous Cell Carcinoma of the Vulva Tisotumab Vedotin - Vulvar Carcinoma, Recurrent or Metastatic Vulvar Cancer | Phase 2 | Not yet recruiting | GOG Foundation | 28 | 2026-11-01 | 2026-06-29 |
| A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) Sacituzumab Tirumotecan, Pemetrexed, Tisotumab Vedotin - Cervical Cancer | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 686 | 2024-07-24 | 2026-08-28 |
| To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies Tisotumab Vedotin - Solid Malignancies | Phase 1 | Completed | Zai Lab (Shanghai) Co., Ltd. | 19 | 2023-06-16 | 2023-11-27 |
| Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer tisotumab vedotin, topotecan, vinorelbine - Cervical Cancer | Phase 3 | Completed | Seagen, a wholly owned subsidiary of Pfizer | 502 | 2021-02-22 | 2026-02-24 |
| A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208) tisotumab vedotin - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Completed | Seagen Inc. | 98 | 2019-03-20 | 2023-05-06 |
| Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer Tisotumab Vedotin, Bevacizumab, Pembrolizumab - Cervical Cancer | Phase 1 / Phase 2 | Terminated | Seagen, a wholly owned subsidiary of Pfizer | 214 | 2019-02-27 | 2026-07-22 |
| A Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies tisotumab vedotin - Solid Tumor | Phase 1 / Phase 2 | Completed | Genmab | 23 | 2019-02-27 | 2022-06-23 |
| Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors tisotumab vedotin, pembrolizumab, carboplatin - Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung | Phase 2 | Active not recruiting | Seagen, a wholly owned subsidiary of Pfizer | 350 | 2018-06-25 | 2026-07-22 |
| A Trial of Tisotumab Vedotin in Cervical Cancer tisotumab vedotin - Cervical Cancer | Phase 2 | Completed | Seagen Inc. | 102 | 2018-06-12 | 2023-07-25 |
| Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors. Tisotumab Vedotin - Ovary Cancer, Cervix Cancer | Phase 2 | Completed | Seagen Inc. | 5 | 2017-08-23 | 2021-11-04 |
| Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors Tisotumab vedotin (HuMax-TF-ADC) - Ovary Cancer, Cervix Cancer | Phase 1 / Phase 2 | Completed | Seagen Inc. | 33 | 2015-11-30 | 2021-04-08 |
| Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors Tisotumab Vedotin (HuMax-TF-ADC) - Ovary Cancer, Cervix Cancer | Phase 1 / Phase 2 | Completed | Seagen Inc. | 195 | 2013-11-30 | 2021-12-29 |
Uterine Cervical Neoplasms (8) · Ovarian Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (3) · Endometrial Neoplasms (3) · Esophageal Neoplasms (3) · Prostatic Neoplasms (3) · Squamous Cell Carcinoma of Head and Neck (3) · Urinary Bladder Neoplasms (3) · Neoplasm Metastasis (2) · Carcinoma, Squamous Cell (1) · Colorectal Neoplasms (1) · Fallopian Tube Neoplasms (1) · Head and Neck Neoplasms (1) · Lung Neoplasms (1) · Pancreatic Neoplasms (1)
Seagen Inc. (5) · Seagen, a wholly owned subsidiary of Pfizer (3) · GOG Foundation (1) · Genmab (1) · Merck Sharp & Dohme LLC (1) · Zai Lab (Shanghai) Co., Ltd. (1)
United States (10) · Belgium (7) · United Kingdom (7) · Denmark (6) · Italy (6) · Spain (6) · Germany (4) · Sweden (4) · Canada (3) · China (3) · Czechia (3) · France (3) · Ireland (3) · Japan (3) · Netherlands (3)
Johann de Bono, Professor (2) · Bingzhong Zhang, Dr (1) · Brian Slomovitz, MD (1) · Dongqing Lv, Dr (1) · Guiling Li, Dr (1) · Jianhua Shi, Dr (1) · Keiichi Fujiwara, Professor (1) · Kristi Schmidt, MD (1) · Meili Sun, Dr (1) · Qing Wen, Dr (1) · Rutie Yin, Dr (1) · Tienan Yi, Dr (1) · Yovanni Casablanca, MD (1)
PMID 41044356, PMID 37496366, PMID 30745090, PMID 31796521, PMID 33845034, PMID 35633184, PMID 37651655, PMID 38959480, PMID 41644383, PMID 42000372, PMID 42680635
2023 (3), 2017 (1)